Clinical Reminders in Test Reports to Improve Guideline Compliance

Status Completed

Clinical Trial Summary

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Clinical Trial Description

Background:

Although beta-blockers are known to prolong survival for patients with reduced left ventricular ejection fraction, their use in the community and the VA is suboptimal.

Objectives:

To determine if a reminder attached to the echocardiography report would increase the use of beta-blockers among patients with depressed left ventricular function.

Methods:

We are randomizing consecutive patients undergoing echocardiography at one of three VA echocardiography laboratories with reduced left ventricular ejection fraction (<40%) and no echocardiographic contraindication to beta-blockers (e.g. aortic stenosis) to a reminder for use of beta-blockers or to no reminder. The reminder gives starting doses for two commonly used beta-blockers (carvedilol and metoprolol). Patients are excluded from the analysis if they leave the health care system or die within three months of randomization. The primary outcome is a prescription for a beta-blocker between three and nine months following echocardiography

Status:

The project is complete. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00414401
Study type	Interventional
Source	VA Office of Research and Development
Contact
Status	Completed
Phase	N/A
Start date	May 2001
Completion date	June 2006

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01357850` - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure	Phase 2
Recruiting	`NCT00532688` - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure	Phase 2/Phase 3
Terminated	`NCT00383630` - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure	Phase 2
Completed	`NCT00531661` - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients	N/A
Completed	`NCT00149435` - Cardiovascular Health Study (CHS) Events Follow-up Study
Terminated	`NCT00125437` - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy	N/A
Completed	`NCT00241761` - Epidemiology of Depression and Heart Failure in Aging	N/A
Completed	`NCT00159614` - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment	Phase 2
Completed	`NCT00094263` - Long-Term Predictors of Morbidity in Older Age	N/A
Terminated	`NCT00357591` - Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation	N/A
Completed	`NCT00202579` - Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure	Phase 2
Completed	`NCT00048425` - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.	Phase 3
Completed	`NCT00023556` - Genetic Architecture of Heart Disease in Rural Brazil	N/A
Completed	`NCT00530426` - Heart Failure Registry	Phase 4
Terminated	`NCT00190359` - Growth Hormone and Heart Failure	N/A
Completed	`NCT00004562` - Occluded Artery Trial (OAT)	Phase 3
Completed	`NCT00005265` - Natural History of Coronary Heart Disease	N/A
Completed	`NCT02772068` - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a	Early Phase 1
Completed	`NCT02925546` - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets	Phase 1
Completed	`NCT01074307` - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea	Phase 4